Oruka Therapeutics, Inc. Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc.

ORKA

Hisse Senetlerindeki Sıralama #3268
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Hisse Fiyatı
$81.14
Piyasa Değeri
$5.37B
Değişim (1 gün)
1.53%
Değişim (1 yıl)
204.47%
Ülke
US
Ticaret Oruka Therapeutics, Inc. (ORKA)

Kategori

Healthcare
Oruka Therapeutics, Inc. (ORKA) için P/S oranı
October 2026 itibarıyla P/S oranı TTM: 0.00
Oruka Therapeutics, Inc. şirketinin en son mali raporları ve hisse fiyatına göre, mevcut P/S oranı (TTM) 0.00'dir. 2024 yılının sonunda şirketin P/S oranı 0.00 idi.
Oruka Therapeutics, Inc. için P/S oranı geçmişi 2005 - 2026 arası
Her yılın sonunda P/S oranı
Yıl P/S Oranı Değiştir
2026 (TTM) 0.00 0.00%
2025 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 -100.00%
2007 2.08 -96.07%
2006 52.93 -91.38%
2005 614.26 0.00%
Benzer şirketler veya rakipler için P/S oranı
Şirket P/S Oranı P/S Oranı Farkı Ülke
10.72 -
US
41.70 -
US
4.19 -
AU
5.80 -
BE
10.44 -
NL